{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:50:06Z","timestamp":1775515806583,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,4,28]]},"DOI":"10.1038\/s41388-026-03723-x","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:44:25Z","timestamp":1774284265000},"page":"1312-1323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aryl hydrocarbon receptor is critical for both AR-dependent and AR-indifferent enzalutamide resistance in castration-resistant prostate cancer"],"prefix":"10.1038","volume":"45","author":[{"given":"Chia-Hui","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-5698","authenticated-orcid":false,"given":"Donald J.","family":"Vander Griend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-9038","authenticated-orcid":false,"given":"Allen C.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-3573","authenticated-orcid":false,"given":"Boyang Jason","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"3723_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clinicians. 2024;74:12\u201349.","journal-title":"CA: A Cancer J Clinicians"},{"key":"3723_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683\u2013722.","journal-title":"Lancet"},{"key":"3723_CR3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437\u201346.","journal-title":"Lancet"},{"key":"3723_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"3723_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382:2197\u2013206.","journal-title":"N Engl J Med"},{"key":"3723_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","volume":"174","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018;174:433\u201347.e419.","journal-title":"Cell"},{"key":"3723_CR7","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"3723_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","volume":"73","author":"Y Li","year":"2013","unstructured":"Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483\u20139.","journal-title":"Cancer Res"},{"key":"3723_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","volume":"3","author":"JD Joseph","year":"2013","unstructured":"Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3:1020\u20139.","journal-title":"Cancer Discov"},{"key":"3723_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104287","volume":"25","author":"R Huhtaniemi","year":"2022","unstructured":"Huhtaniemi R, Sipila P, Junnila A, Oksala R, Knuuttila M, Mehmood A, et al. High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice. iScience. 2022;25:104287.","journal-title":"iScience"},{"key":"3723_CR11","first-page":"1413","volume":"75","author":"C Liu","year":"2015","unstructured":"Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, et al. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res (Res Support, NIH, Extramural). 2015;75:1413\u201322.","journal-title":"Cancer Res (Res Support, NIH, Extramural)"},{"key":"3723_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21860-7","volume":"12","author":"Y He","year":"2021","unstructured":"He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, et al. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021;12:1521.","journal-title":"Nat Commun"},{"key":"3723_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309\u201322.","journal-title":"Cell"},{"key":"3723_CR14","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1038\/s41388-021-01754-0","volume":"40","author":"M Puhr","year":"2021","unstructured":"Puhr M, Eigentler A, Handle F, Hackl H, Ploner C, Heidegger I, et al. Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. Oncogene. 2021;40:3087\u20133100.","journal-title":"Oncogene"},{"key":"3723_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41388-024-03252-5","volume":"44","author":"S Dutta","year":"2025","unstructured":"Dutta S, Khedmatgozar H, Patel GK, Latour D, Welsh J, Mustafi M, et al. A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer. Oncogene. 2025;44:877\u201392.","journal-title":"Oncogene"},{"key":"3723_CR16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1158\/2159-8290.CD-21-0576","volume":"12","author":"S Linder","year":"2022","unstructured":"Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, et al. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discov. 2022;12:2074\u201397.","journal-title":"Cancer Discov"},{"key":"3723_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/pros.24297","volume":"82","author":"JM Moll","year":"2022","unstructured":"Moll JM, Hofland J, Teubel WJ, de Ridder CMA, Taylor AE, Graeser R, et al. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. Prostate. 2022;82:505\u201316.","journal-title":"Prostate"},{"key":"3723_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/1078-0432.CCR-17-0989","volume":"24","author":"M Puhr","year":"2018","unstructured":"Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, et al. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2018;24:927\u201338.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"3723_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"3723_CR20","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129:4492\u2013505.","journal-title":"J Clin Invest"},{"key":"3723_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26042-z","volume":"12","author":"P Cejas","year":"2021","unstructured":"Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021;12:5775.","journal-title":"Nat Commun"},{"key":"3723_CR22","doi-asserted-by":"publisher","first-page":"26137","DOI":"10.18632\/oncotarget.8433","volume":"7","author":"TP Lin","year":"2016","unstructured":"Lin TP, Chang YT, Lee SY, Campbell M, Wang TC, Shen SH, et al. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling. Oncotarget. 2016;7:26137\u201351.","journal-title":"Oncotarget"},{"key":"3723_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","volume":"29","author":"JK Lee","year":"2016","unstructured":"Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer cell. 2016;29:536\u201347.","journal-title":"Cancer cell"},{"key":"3723_CR24","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","volume":"12","author":"S Akamatsu","year":"2015","unstructured":"Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, et al. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Rep. 2015;12:922\u201336.","journal-title":"Cell Rep"},{"key":"3723_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08133-6","volume":"10","author":"H Guo","year":"2019","unstructured":"Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019;10:278.","journal-title":"Nat Commun"},{"key":"3723_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101970","volume":"24","author":"T Bland","year":"2021","unstructured":"Bland T, Wang J, Yin L, Pu T, Li J, Gao J, et al. WLS-Wnt signaling promotes neuroendocrine prostate cancer. iScience. 2021;24:101970.","journal-title":"iScience"},{"key":"3723_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrc3846","volume":"14","author":"IA Murray","year":"2014","unstructured":"Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2014;14:801\u201314.","journal-title":"Nat Rev Cancer"},{"key":"3723_CR28","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik A, Somarribas Patterson LF, Ozturk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell. 2020;182:1252\u201370.e1234.","journal-title":"Cell"},{"key":"3723_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bcp.2012.12.010","volume":"85","author":"C Tran","year":"2013","unstructured":"Tran C, Richmond O, Aaron L, Powell JB. Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells. Biochemical Pharmacol. 2013;85:753\u201362.","journal-title":"Biochemical Pharmacol"},{"key":"3723_CR30","doi-asserted-by":"publisher","first-page":"e95058","DOI":"10.1371\/journal.pone.0095058","volume":"9","author":"O Richmond","year":"2014","unstructured":"Richmond O, Ghotbaddini M, Allen C, Walker A, Zahir S, Powell JB. The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells. PloS one. 2014;9:e95058.","journal-title":"PloS one"},{"key":"3723_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/carcin\/bgl179","volume":"28","author":"WA Fritz","year":"2007","unstructured":"Fritz WA, Lin TM, Cardiff RD, Peterson RE. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis. 2007;28:497\u2013505.","journal-title":"Carcinogenesis"},{"key":"3723_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsbmb.2003.10.005","volume":"88","author":"D Morrow","year":"2004","unstructured":"Morrow D, Qin C, Smith R 3rd, Safe S. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J Steroid Biochem Mol Biol. 2004;88:27\u201336.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3723_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0236-x","volume":"9","author":"Z Chen","year":"2020","unstructured":"Chen Z, Cai A, Zheng H, Huang H, Sun R, Cui X, et al. Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor. Oncogenesis. 2020;9:49.","journal-title":"Oncogenesis"},{"key":"3723_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/carcin\/bgv040","volume":"36","author":"F Sun","year":"2015","unstructured":"Sun F, Indran IR, Zhang ZW, Tan MH, Li Y, Lim ZL, et al. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. Carcinogenesis. 2015;36:757\u201368.","journal-title":"Carcinogenesis"},{"key":"3723_CR35","doi-asserted-by":"publisher","first-page":"26259","DOI":"10.18632\/oncotarget.8456","volume":"7","author":"S Kregel","year":"2016","unstructured":"Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, et al. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget. 2016;7:26259\u201374.","journal-title":"Oncotarget"},{"key":"3723_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/cr.2008.63","volume":"18","author":"PP Ho","year":"2008","unstructured":"Ho PP, Steinman L. The aryl hydrocarbon receptor: a regulator of Th17 and Treg cell development in disease. Cell Res. 2008;18:605\u20138.","journal-title":"Cell Res"},{"key":"3723_CR37","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1038\/s41388-022-02444-1","volume":"41","author":"C Li","year":"2022","unstructured":"Li C, Liu J, He D, Mao F, Rao X, Zhao Y, et al. GSTM2 is a key molecular determinant of resistance to SG-ARIs. Oncogene. 2022;41:4498\u2013511.","journal-title":"Oncogene"},{"key":"3723_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.toxlet.2011.07.011","volume":"206","author":"E Hruba","year":"2011","unstructured":"Hruba E, Vondracek J, Libalova H, Topinka J, Bryja V, Soucek K, et al. Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands. Toxicol Lett. 2011;206:178\u201388.","journal-title":"Toxicol Lett"},{"key":"3723_CR39","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3723_CR40","doi-asserted-by":"publisher","first-page":"e162907.","DOI":"10.1172\/jci.insight.162907","volume":"8","author":"E Sayar","year":"2023","unstructured":"Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;8:e162907.","journal-title":"JCI Insight"},{"key":"3723_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.bcp.2008.08.034","volume":"77","author":"F Ohtake","year":"2009","unstructured":"Ohtake F, Fujii-Kuriyama Y, Kato S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochemical Pharmacol. 2009;77:474\u201384.","journal-title":"Biochemical Pharmacol"},{"key":"3723_CR42","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/0008-5472.CAN-21-0198","volume":"81","author":"J Wei","year":"2021","unstructured":"Wei J, Yin L, Li J, Wang J, Pu T, Duan P, et al. Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer. Cancer Res. 2021;81:4275\u201389.","journal-title":"Cancer Res"},{"key":"3723_CR43","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/sj.onc.1206764","volume":"22","author":"XQ Zhang","year":"2003","unstructured":"Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene. 2003;22:6704\u201316.","journal-title":"Oncogene"},{"key":"3723_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov. 2017;7:54\u201371.","journal-title":"Cancer Discov"},{"key":"3723_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18:79\u201392.","journal-title":"Nat Rev Urol"},{"key":"3723_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115626","volume":"213","author":"L Sladekova","year":"2023","unstructured":"Sladekova L, Mani S, Dvorak Z. Ligands and agonists of the aryl hydrocarbon receptor AhR: Facts and myths. Biochemical Pharmacol. 2023;213:115626.","journal-title":"Biochemical Pharmacol"},{"key":"3723_CR47","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cellsig.2005.07.007","volume":"18","author":"S Gerbal-Chaloin","year":"2006","unstructured":"Gerbal-Chaloin S, Pichard-Garcia L, Fabre JM, Sa-Cunha A, Poellinger L, Maurel P, et al. Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. Cell Signal. 2006;18:740\u201350.","journal-title":"Cell Signal"},{"key":"3723_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/toxsci\/kfq217","volume":"117","author":"B Zhao","year":"2010","unstructured":"Zhao B, Degroot DE, Hayashi A, He G, Denison MS. CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. Toxicol Sci. 2010;117:393\u2013403.","journal-title":"Toxicol Sci"},{"key":"3723_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20572-2","volume":"12","author":"JC Granados","year":"2022","unstructured":"Granados JC, Falah K, Koo I, Morgan EW, Perdew GH, Patterson AD, et al. AHR is a master regulator of diverse pathways in endogenous metabolism. Sci Rep. 2022;12:16625.","journal-title":"Sci Rep"},{"key":"3723_CR50","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Tapinarof Cream 1%: First Approval. Drugs. 2022;82:1221\u20138.","journal-title":"Drugs"},{"key":"3723_CR51","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res: Off J Am Assoc Cancer Res. 2019;25:6916\u201324.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"3723_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115371","volume":"208","author":"NC Sondermann","year":"2023","unstructured":"Sondermann NC, Fassbender S, Hartung F, Hatala AM, Rolfes KM, Vogel CFA, et al. Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR\/ARNT signaling pathway. Biochemical Pharmacol. 2023;208:115371.","journal-title":"Biochemical Pharmacol"},{"key":"3723_CR53","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science. 2022;377:1180\u201391.","journal-title":"Science"},{"key":"3723_CR54","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","volume":"3","author":"S Deng","year":"2022","unstructured":"Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, et al. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat Cancer. 2022;3:1071\u201387.","journal-title":"Nat Cancer"},{"key":"3723_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112288","volume":"396","author":"J Xiong","year":"2020","unstructured":"Xiong J, Zhang X, Zhang Y, Wu B, Fang L, Wang N, et al. Aryl hydrocarbon receptor mediates Jak2\/STAT3 signaling for non-small cell lung cancer stem cell maintenance. Exp Cell Res. 2020;396:112288.","journal-title":"Exp Cell Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03723-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03723-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03723-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:01:37Z","timestamp":1775512897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03723-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":55,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,4,28]]}},"alternative-id":["3723"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03723-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All animal studies received prior approval from the Institutional Animal Care and Use Committee (IACUC) at Washington State University (No. 6635) and complied with IACUC recommendations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}